Opposite effects of allergy prevention depending on CD14 rs2569190 genotype in 3 intervention studies

• Published in: Journal of allergy and clinical immunology 2012-01, Vol.129 (1), p.256-259
• Main Authors: Kerkhof, Marjan, MD, PhD, Daley, Denise, PhD, Postma, Dirkje S., MD, PhD, Park, Julie E., MMath, Chan Yeung, Moira, MD, Wijga, Alet H., PhD, Gehring, Ulrike, PhD, de Jongste, Johan C., MD, PhD, Smit, Henriëtte A., PhD, Brunekreef, Bert, PhD, van Schayck, Onno C.P., MD, PhD, Becker, Allan, MD, Koppelman, Gerard H., MD, PhD
• Format: Article
• Language: English
• Subjects: Age; Allergies; Allergy and Immunology; Asthma; Biological and medical sciences; Child; Child, Preschool; Children & youth; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Genotype; Humans; Hypersensitivity - genetics; Hypersensitivity - immunology; Hypersensitivity - prevention & control; Immunoglobulin E - immunology; Immunopathology; Infant; Infant, Newborn; Intervention; Lipopolysaccharide Receptors - genetics; Male; Medical sciences; Risk Factors; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2011.08.040

PIAMA cohort, age 8 y CT or CC TT Active IMC group Placebo IMC group NHS high-risk group Active IMC group Placebo IMC group NHS high-risk group CAPPS cohort, age 7 y CT or CC TT Active MFI group Control group Active MFI group Control group PREVASC cohort, age 6 y CT or CC TT Active MFI group Control group Active MFI group Control group Atopy 24.1 (32/133) 27.8 (27/97) 22.8 (29/127) 42.9[low *] (12/28) 11.1 (3/27) 27.5 (11/40) Total IgE (IU/mL) 63.0 (136) 81.7 (103) 54.6 (117) 145.1[low *] (34) 42.2 (25) 71.6 (38) Asthma symptoms last 12 mo 19.3 (31/161) 16.5 (21/127) 19.4 (31/160) 30.6 (11/36) 17.9 (5/28) 21.6 (11/51) Diagnosed asthma last 12 mo 5.4 (8/148) 5.0 (6/121) 3.8 (6/158) 11.4[dagger] (4/35) 7.4 (2/27) 0 (0/49) Atopy 50.5[low *] (55/109) 31.3 (31/99) 44.4 (12/27) 51.7 (15/29) Total IgE (IU/mL) 22.2 (98) 17.1 (90) 22.9 (25) 26.0 (24) Asthma symptoms last 12 mo NA NA NA NA Diagnosed asthma last 12 mo 16.1 (18/112) 23.5 (24/102) 10.7 (3/28) 26.7 (8/30) Atopy NA NA NA NA Total IgE (IU/mL) 24.7 (87) 17.3 (78) 33.4 (24) 19.0 (18) Asthma symptoms last 12 mo 25.0 (19/76) 19.5 (17/87) 13.0 (3/23) 26.7 (4/11) Diagnosed asthma last 12 mo 22.2 (18/81) 14.1 (13/92) 12.5 (3/24) 22.2 (4/15) Table II Distribution of asthma and allergy outcomes in the intervention, placebo, and control groups for the PIAMA study, CAPPS, and the PREVASC study stratified by CD14/rs2569190 genotype Data are presented as percentages (numbers affected/total numbers) or geometric means (total numbers).Boldface values are significant: [low *]P < .05 compared with placebo or control group and [dagger]P < .05 compared with natural history study high-risk group.MFI, Multifaceted intervention; NA, not available; NHS, natural history study.